esfera / Shutterstock.com
8 May 2025NewsEuropeSarah Speight

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

Industry body says agreement doesn’t address ‘longstanding industry concerns’ about IP | Deal criticised for ‘lack of detail’ on IP, particularly for UK life sciences and general legal sector | £25.5bn deal offers provisions for medical devices | Smith+Nephew hopes deal will help build trade for healthcare.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
15 January 2026   Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.
Europe
13 January 2026   As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.
Europe
9 January 2026   Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.